Holen Sie sich die Stockscreener-App
1.89
3.57%
-0.07
Handel nachbörslich:
1.89
Schlusskurs vom Vortag:
$1.96
Offen:
$1.95
24-Stunden-Volumen:
1.39M
Relative Volume:
1.07
Marktkapitalisierung:
$305.70M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-274.18M
KGV:
-0.7457
EPS:
-2.5346
Netto-Cashflow:
$-198.33M
1W Leistung:
+30.34%
1M Leistung:
+140.55%
6M Leistung:
-9.13%
1J Leistung:
-83.72%
1-Tages-Spanne:
$1.80
$1.98
1-Wochen-Bereich:
$1.31
$2.17
52-Wochen-Spanne:
$0.611
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Firmenname
Neumora Therapeutics Inc
Sektor
Branche
Telefon
(857) 760-0900
Adresse
490 ARSENAL WAY, SUITE 200, WATERTOWN
Vergleichen Sie NMRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.89 | 234.53M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-07 | Herabstufung | Stifel | Buy → Hold |
| 2025-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-10 | Eingeleitet | BofA Securities | Buy |
| 2023-10-10 | Eingeleitet | Guggenheim | Buy |
| 2023-10-10 | Eingeleitet | JP Morgan | Overweight |
| 2023-10-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-10 | Eingeleitet | Stifel | Buy |
| 2023-10-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
What analysts say about Neumora Therapeutics Inc. stockMarket-leading profit generation - Autocar Professional
What drives Neumora Therapeutics Inc. stock priceUnmatched profit growth - jammulinksnews.com
Neumora Therapeutics Inc. Stock Analysis and ForecastExplosive capital appreciation - jammulinksnews.com
Is Neumora Therapeutics Inc. a good long term investmentTriple-digit profit margins - jammulinksnews.com
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by Analysts - MarketBeat
Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating - Yahoo Finance
How Neumora Therapeutics Inc. stock reacts to Fed policy changesEntry Level Low Risk Picks - Newser
10 Hot Penny Stocks to Invest in Now - Insider Monkey
Neumora Therapeutics (NASDAQ:NMRA) Given New $5.00 Price Target at Mizuho - MarketBeat
Mizuho raises Neumora Therapeutics stock price target on new drug candidate - Investing.com Canada
Why Neumora Therapeutics Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser
How Neumora Therapeutics Inc. stock performs during market volatilityCarefully Curated High Return Stocks - Newser
What makes Neumora Therapeutics Inc. stock price move sharplyReturn Optimized Trade Insights - Newser
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Solid Biosciences (SLDB) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
FibroBiologics (NASDAQ:FBLG) vs. Neumora Therapeutics (NASDAQ:NMRA) Head to Head Contrast - Defense World
Neumora Therapeutics (NMRA) Soars 33.02% on Drug Trial Advancement - AInvest
H.C. Wainwright reiterates Buy rating on Neumora Therapeutics stock By Investing.com - Investing.com Canada
Neumora begins phase 1 trial of schizophrenia drug NMRA-861 By Investing.com - Investing.com South Africa
Neumora Therapeutics’ Promising M4 PAM Program Drives Buy Rating with $18 Price Target - TipRanks
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 - The Manila Times
Neumora begins phase 1 trial of schizophrenia drug NMRA-861 - Investing.com
Aldeyra Therapeutics Leads The Pack Among 3 Promising Penny Stocks - simplywall.st
Lunate Capital Ltd Acquires Shares of 2,124,143 Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $9.29 Consensus Target Price from Analysts - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by California State Teachers Retirement System - Defense World
72,622 Shares in Neumora Therapeutics, Inc. (NASDAQ:NMRA) Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Shareholders Filed a Lawsuit Against Neumora Therapeutics for Misleading Drug Trial Claims - TradingView
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Finanzdaten der Neumora Therapeutics Inc-Aktie (NMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):